By Cara Bayles ( October 24, 2017, 9:18 PM EDT) -- Investors claiming the immunotherapy company Juno Therapeutics failed to inform them of the health risks associated with one of its drugs received class certification on Tuesday in Washington federal court, and Pomerantz LLP was appointed lead class counsel....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.